---
title: "Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297951172.md"
description: "Summit Therapeutics stock surged after its experimental cancer drug outperformed Merck's Keytruda in trials, sparking investor optimism. However, industry skepticism remains regarding the drug's superiority, potentially reshaping the cancer treatment landscape."
datetime: "2026-09-03T19:26:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297951172.md)
  - [en](https://longbridge.com/en/news/297951172.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297951172.md)
generator: "portal-rs"
---

# Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold

Thursday saw a significant surge in Summit Therapeutics stock following the success of its experimental cancer drug, surpassing the performance of Merck's popular drug Keytruda. This outcome has raised eyebrows in the pharmaceutical industry. The results suggest that Summit's drug has the potential to outperform Keytruda, a major player in the market. The unexpected success has made investors bullish on Summit Therapeutics, causing a surge in its stock value. However, not all parties are convinced of the drug's superiority over Keytruda. This development could potentially shake up the current landscape of cancer treatment.

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Akeso, Summit cancer drug confirms lung cancer survival benefit](https://longbridge.com/en/news/298059867.md)
- [Merck (MRK), Why Is Its Latest Update Raising Bigger Questions?](https://longbridge.com/en/news/298090109.md)
- [India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar](https://longbridge.com/en/news/297935089.md)
- [Novartis Just Lost a Potential $6 Billion Drug Opportunity](https://longbridge.com/en/news/298222548.md)
- [Why Akeso (SEHK:9926) Is Up 6.8% After Ivonescimab Tops Key Cancer Rivals In Phase III Trials – And What's Next](https://longbridge.com/en/news/298227113.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**